Targeting BRD4 bromodomains and beyond: exploring new therapeutic frontiers
Trends in Pharmacological Sciences · 2026
DOI: 10.1016/j.tips.2025.09.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2026. Verfasst von Wenju Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, The First Hospital, Jilin University, Changchun 130021, China; International Center of Future Science, Jilin Uni…. Hauptthemen laut MEDLINE: Transcription Factors, Cell Cycle Proteins, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Key Laboratory of Supramolecular Structure and Materials, Jilin University, First Hospital of Jilin University.
Abstract (Originalsprache)
Bromodomain-containing protein 4 (BRD4) is a key transcriptional regulator in the bromodomain and extraterminal (BET) family. It promotes cancer and inflammation by binding to chromatin through its bromodomains. Although bromodomain inhibitors (e.g., BETi) show preclinical efficacy, their clinical application has been limited primarily by dose-limiting toxicities (DLTs), with resistance emerging as a secondary challenge. This motivates the development of strategies beyond conventional bromodomain inhibition. Here, we review emerging evidence that BRD4 sustains oncogenic programs through bromodomain-independent mechanisms, and discuss innovative approaches designed to overcome DLT. These include BRD4-targeted degraders, nonbromodomain ligands that disrupt scaffolding functions, post-translational modification (PTM) disruptors, and condensate modulators. We also discuss advances in chemically induced proximity (CIP) platforms that enable disease-state transcriptional reprogramming, and rational combination therapies (e.g., epigenetic-kinase inhibitors and BETi-immunotherapy integration) that minimize toxicity while addressing emerging resistance. Together, these approaches open new therapeutic frontiers for treating BRD4-driven diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Translational Medicine, The First Hospital, Jilin University, Changchun 130021, China; International Center of Future Science, Jilin University, Changchun 130012, China.
- Department of Pediatric Intensive Care Unit, The First Hospital, Jilin University, Changchun 130021, China. Electronic address: ym_li@jlu.edu.cn.
- Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: ming-ming.zhou@mssm.edu.
- Institute of Translational Medicine, The First Hospital, Jilin University, Changchun 130021, China; International Center of Future Science, Jilin University, Changchun 130012, China. Electronic address: leizeng@jlu.edu.…
Förderung
- State Key Laboratory of Supramolecular Structure and Materials
- Jilin University
- First Hospital of Jilin University
- Program for Jilin University Science and Technology Innovative Research Team
- National Natural Science Foundation of China
Zitieren
APA
Zhang, W., Li, Y., Zhou, M. M., & Zeng, L. (2026). Targeting BRD4 bromodomains and beyond: exploring new therapeutic frontiers. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2025.09.006
Vancouver
Zhang W, Li Y, Zhou MM, Zeng L. Targeting BRD4 bromodomains and beyond: exploring new therapeutic frontiers. Trends in Pharmacological Sciences. 2026. doi:10.1016/j.tips.2025.09.006
BibTeX
@article{Zhang2026,
author = {Zhang, Wenju and Li, Yumei and Zhou, Ming-Ming and Zeng, Lei},
title = {Targeting BRD4 bromodomains and beyond: exploring new therapeutic frontiers},
journal = {Trends in Pharmacological Sciences},
year = {2026},
doi = {10.1016/j.tips.2025.09.006}
}
EUVIMED